Scholarlink

Introduction <p>Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1–3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician’s choice of treatment for lenalidomide-refractory MM.</p> Methods <p>De-identified data from the Flatiron Health MM cohort registry (January 2020 to May&#xa0;2024) were compared with data from CARTITUDE-4 (data cutoff May&#xa0;1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from the Flatiron database. Baseline covariates of prognostic significance were adjusted using inverse probability of treatment weighting. Outcomes for comparative effectiveness included progression-free survival (PFS), RW PFS, time to next treatment (TTNT), and overall survival (OS). Sensitivity analyses were conducted.</p> Results <p>The CARTITUDE-4 cohort included data from 208 patients who received cilta-cel; the median follow-up was 33.6&#xa0;months. The real-world cohort included 932 patients (1445 eligible LOT) from the Flatiron database; the median follow-up was 23.6&#xa0;months. In base case analyses, compared with the Flatiron cohort, patients treated with cilta-cel had improved PFS (hazard ratio [HR] 0.29 [95% confidence interval (CI)] 0.22–0.36; <i>p</i> &lt; 0.001), RW-PFS (HR 0.29 [95%&#xa0;CI 0.23–0.37]; <i>p</i> &lt; 0.001), TTNT (HR 0.32 [95%&#xa0;CI 0.25–0.41]; <i>p</i> &lt; 0.001), and OS (HR 0.59 [95%&#xa0;CI 0.41–0.84]; <i>p</i> = 0.003). These findings were consistent across all sensitivity analyses.</p> Conclusion <p>Cilta-cel lengthened TTNT and demonstrated meaningful prolongation in PFS and OS compared with real-world physician’s choice for lenalidomide-refractory MM. These data highlight the value of cilta-cel as an effective therapy in earlier-line patients with relapsed, lenalidomide-refractory MM exposed to proteasome inhibitors and immunomodulatory drugs.</p> Trial registration <p>CARTITUDE-4: ClinicalTrials.gov ID NCT04181827.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Cyrille Touzeau,
  • Brea Lipe,
  • Abdullah M. Khan,
  • Binod Dhakal,
  • Sandhya Nair,
  • Jianming He,
  • João Mendes,
  • Seina Lee,
  • Carolina Lonardi,
  • Ana Slaughter,
  • Nikoletta Lendvai,
  • Jordan M. Schecter,
  • Diana Chen,
  • Man Zhao,
  • Tzu-min Yeh,
  • Xavier Leleu,
  • Noemí Puig,
  • Dominik Dytfeld,
  • Elena Zamagni,
  • Katja Weisel,
  • Lionel Karlin,
  • Michel Delforge,
  • Paolo Corradini,
  • Roberto Mina,
  • Wilfried Roeloffzen,
  • Surbhi Sidana

摘要

Introduction

Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1–3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician’s choice of treatment for lenalidomide-refractory MM.

Methods

De-identified data from the Flatiron Health MM cohort registry (January 2020 to May 2024) were compared with data from CARTITUDE-4 (data cutoff May 1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from the Flatiron database. Baseline covariates of prognostic significance were adjusted using inverse probability of treatment weighting. Outcomes for comparative effectiveness included progression-free survival (PFS), RW PFS, time to next treatment (TTNT), and overall survival (OS). Sensitivity analyses were conducted.

Results

The CARTITUDE-4 cohort included data from 208 patients who received cilta-cel; the median follow-up was 33.6 months. The real-world cohort included 932 patients (1445 eligible LOT) from the Flatiron database; the median follow-up was 23.6 months. In base case analyses, compared with the Flatiron cohort, patients treated with cilta-cel had improved PFS (hazard ratio [HR] 0.29 [95% confidence interval (CI)] 0.22–0.36; p < 0.001), RW-PFS (HR 0.29 [95% CI 0.23–0.37]; p < 0.001), TTNT (HR 0.32 [95% CI 0.25–0.41]; p < 0.001), and OS (HR 0.59 [95% CI 0.41–0.84]; p = 0.003). These findings were consistent across all sensitivity analyses.

Conclusion

Cilta-cel lengthened TTNT and demonstrated meaningful prolongation in PFS and OS compared with real-world physician’s choice for lenalidomide-refractory MM. These data highlight the value of cilta-cel as an effective therapy in earlier-line patients with relapsed, lenalidomide-refractory MM exposed to proteasome inhibitors and immunomodulatory drugs.

Trial registration

CARTITUDE-4: ClinicalTrials.gov ID NCT04181827.